echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Takeda Takhzyro Approved in Japan to Prevent Hereditary Angioedema

    Takeda Takhzyro Approved in Japan to Prevent Hereditary Angioedema

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompileDraven

    On March 28, the Japanese Ministry of Health approved Takeda Takhzyro (lanadelumab) 300mg subcutaneous injection as a preventive treatment drug for Japanese patients over 12 years old with hereditary angioedema (HAE)


    The approval is based primarily on the global Phase 3 HELP Study, the Phase 3 HEL Open-Label Extension (OLE) study, and a Phase 3 clinical trial in Japanese patients


    The HELP Study and HELP OLE are the largest randomized controlled clinical prevention studies conducted in HAE to date, involving 125 patients with HAE


    In the phase 3 study conducted in Japan, 41.


    Takhzyro was originally developed by Shire, which Takeda acquired in May 2018 for $62 billion for Shire


    It is reported that Takhzyro was approved by the United States and the European Union in August and November 2018, and has been approved in more than 50 countries so far


    In terms of drug mechanism, the half-life of Takhzyro in HAE patients is 14 days.


    Reference source: Takeda's Takhzyro® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.